Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • JnJ directed to pay...

    JnJ directed to pay USD 572 million for opioid addiction crisis

    Medical Dialogues BureauWritten by Medical Dialogues Bureau Published On 2019-08-27T09:20:12+05:30  |  Updated On 27 Aug 2019 9:20 AM IST
    JnJ directed to pay USD 572 million for opioid addiction crisis

    Norman (US): An Oklahoma judge on Monday found Johnson and Johnson(JnJ) and its subsidiaries helped fuel the state's opioid drug crisis and ordered the consumer products giant to pay USD 572 million to help abate the problem in the coming years.


    Cleveland County District Judge Thad Balkman's ruling followed the first state opioid case to make it to trial and could help shape negotiations over roughly 1,500 similar lawsuits filed by the state, local and tribal governments consolidated before a federal judge in Ohio.


    "The opioid crisis has ravaged the state of Oklahoma," Balkman said before announcing the verdict. "It must be abated immediately."


    The companies are expected to appeal the ruling to the Oklahoma Supreme Court.


    Before Oklahoma's trial began May 28, Oklahoma reached settlements with two other defendant groups - a USD 270 million deal with OxyContin-maker Purdue Pharma and a USD 85 million settlement with Israeli-owned Teva Pharmaceutical Industries Ltd.


    Oklahoma argued the companies and their subsidiaries created a public nuisance by launching an aggressive and misleading marketing campaign that overstated how effective the drugs were for treating chronic pain and understated the risk of addiction. Oklahoma Attorney General Mike Hunter says opioid overdoses killed 4,653 people in the state from 2007 to 2017.


    Mike Hunter has called Johnson & Johnson a "kingpin" company that was motivated by greed. He specifically pointed to two former Johnson & Johnson subsidiaries, Noramco and Tasmanian Alkaloids, which produced much of the raw opium used by other manufacturers to produce the drugs.


    "They've been the principal origin for the active pharmaceutical ingredient in prescription opioids in the country for the last two decades," Hunter said after the trial ended July 15.


    "It is one of the most important elements of causation with regard to why the defendants ... are responsible for the epidemic in the country and in Oklahoma." Attorneys for the company have maintained they were part of a lawful and heavily regulated industry subject to strict federal oversight, including the US Drug Enforcement Agency and the Food and Drug Administration, during every step of the supply chain.


    Lead attorney Larry Ottaway said during closing arguments that opioid drugs serve a critical health need - to address chronic pain that affects thousands of Oklahomans every day.


    "This problem of untreated chronic pain afflicts people here in Oklahoma," Ottaway said.


    Oklahoma pursued the case under the state's public nuisance statute and presented the judge with a plan to abate the crisis that would cost between USD 12.6 billion for 20 years and USD 17.5 billion over 30 years. Attorneys for Johnson and Johnson(JnJ) have said that estimate is wildly inflated.


    Read Also: Opioid Lawsuit: Oklahoma judge to deliver judgment in first state case

    BalkmandrugmakerJnJJohnson and JohnsonkingpinLarry OttawayMike HunterNoramcoohioOklahomaopioid drug crisisOxyContinpharmapharma companypharma newsPurdue PharmaTasmanian AlkaloidsTeva PharmaceuticalThad BalkmanUS Drug Enforcement Agency
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok